See also
Inborn error of metabolism
Leukocyte adhesion deficiency
PMM2 deficiency

References
External links

GeneReviews/NIH/NCBI/UW entry on PMM2-CDG (CDG-Ia)Carbohydrate-Deficient Glycoprotein Syndrome, Type 1a; Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome
OMIM entries on Carbohydrate-Deficient Glycoprotein Syndrome, Type 1a; Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome
GeneReviews/NIH/NCBI/UW entry on Congenital Disorders of Glycosylation Overview
In 1958, Anthony R. Curreri, Fred J. Ansfield, Forde A. McIver, Harry A. Waisman, and Charles Heidelberger reported the first clinical findings of 5-FUs activity in cancer in humans. Natural analogues
In 2003, scientists isolated 5-fluorouracil derivatives, closely related compounds, from the marine sponge, Phakellia fusca collected around the Yongxing Island of the Xisha Islands in the South China Sea. This is significant because fluorine-containing organic compounds are rare in nature, and  also because manmade anticancer drugs are not frequently found to have analogues in nature. Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. Names
The name "fluorouracil" is the INN, USAN, USP name, and BAN. The form "5-fluorouracil" is often used; it shows that there is a fluorine atom on the 5th carbon of a uracil ring. References
Further reading
Dean L (2016). "Fluorouracil Therapy and DPYD Genotype". In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520376. Bookshelf ID: NBK395610. Latchman, Jessica; Guastella, Ann; Tofthagen, Cindy (1 October 2014). "5-Fluorouracil Toxicity and Dihydropyrimidine Dehydrogenase Enzyme: Implications for Practice". Clinical Journal of Oncology Nursing. 18 (5): 581–585. doi:10.1188/14.CJON.581-585. PMC 5469441. PMID 25253112. External links
"Fluorouracil". Drug Information Portal. U.S. National Library of Medicine. "Fluorouracil Topical". MedlinePlus.